Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity

Journal of Pediatric Urology

Volumn 4, Issue 6, 2008, Pages 428-433

  Reddy, Pramod P ^a   Borgstein, Niels G ^b   Nijman, Rien J M ^c   Ellsworth, Pamela I ^d  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d BROWN UNIVERSITY   (United States)

Author keywords

Bladder; Child; Muscarinic antagonists; Neurogenic; Urinary incontinence

Indexed keywords

TOLTERODINE;

ADOLESCENT; ARTICLE; BLADDER CAPACITY; CHILD; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES INCONTINENCE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INCONTINENCE; INFANT; INFECTION; INTERMITTENT CATHETERIZATION; MALE; MEDIASTINUM DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; THORAX DISEASE; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; URODYNAMICS; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; BENZHYDRYL COMPOUNDS; CHILD; CHILD, PRESCHOOL; CRESOLS; FEMALE; HUMANS; INFANT; MALE; MUSCARINIC ANTAGONISTS; MUSCLE HYPERTONIA; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; TREATMENT OUTCOME; URINARY BLADDER; URODYNAMICS;

EID: 55649108429     PISSN: 14775131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpurol.2008.05.003     Document Type: Article

References (16)

1. van Gool J.D., Dik P., and de Jong T.P. Bladder-sphincter dysfunction in myelomeningocele. Eur J Pediatr 160 (2001) 414-420
2. Aslan A.R., and Kogan B.A. Conservative management in neurogenic bladder dysfunction. Curr Opin Urol 12 (2002) 473-477
3. Madersbacher H.G. Neurogenic bladder dysfunction. Curr Opin Urol 9 (1999) 303-307
4. Buyse G., Verpoorten C., Vereecken R., and Casaer P. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol 160 (1998) 1084-1087 discussion 92
5. Franco I., Horowitz M., Grady R., Adams R.C., De Jong T.P., Lindert K., et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol 173 1 (2005) 221-225
6. Goessl C., Knispel H.H., Fiedler U., Härle B., Steffen-Wilke K., and Miller K. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology 51 1 (1998) 94-98
7. Palmer L.S., Zebold K., Firlit C.F., and Kaplan W.E. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol 157 (1997) 638-640
8. Kaplinsky R., Greenfield S., Wan J., and Fera M. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. J Urol 156 (1996) 753-756
9. Nilvebrant L., Andersson K.E., Gillberg P.G., Stahl M., and Sparf B. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol 327 (1997) 195-207
10. Ayan S., Kaya K., Topsakal K., Kilicarslan H., Gokce G., and Gultekin Y. Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children. BJU Int 96 3 (2005) 411-414
11. Bolduc S., Upadhyay J., Payton J., Bägli D.J., McLorie G.A., Khoury A.E., et al. The use of tolterodine in children after oxybutynin failure. BJU Int 91 4 (2003) 398-401
12. Goessl C., Sauter T., Michael T., Bergé B., Staehler M., and Miller K. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology 55 3 (2000) 414-418
13. Munding M., Wessells H., Thornberry B., and Riden D. Use of tolterodine in children with dysfunctional voiding: an initial report. J Urol 165 (2001) 926-928
14. Nijman R.J., Borgstein N.G., Ellsworth P., and Djurhuus J.C. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. J Urol 173 (2005) 1334-1339
15. Ellsworth P.I., Borgstein N.G., Nijman R.J., and Reddy P.P. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. J Urol 174 (2005) 1647-1651 discussion 51
16. Amark P., Bussman G., and Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 34 (1998) 148-153